BTBP(600161)

Search documents
天坛生物:天坛生物关于对国药集团财务有限公司的风险持续评估报告
2023-08-29 10:11
北京天坛生物制品股份有限公司 关于对国药集团财务有限公司的风险持续评估报告 根据《上海证券交易所上市公司自律监管指引第5号—交易与关联交易》的要求,通 过查验国药集团财务有限公司(以下简称"财务公司"或"公司")《金融许可证》、《营 业执照》等资料,并审阅了包括资产负债表、利润表、现金流量表等在内的定期财务报告, 对其经营资质、业务和风险状况进行了评估,具体情况报告如下: 一、 财务公司基本情况 财务公司成立于2012年2月23日,是经中国银行保险监督管理委员会批准成立的非银 行金融机构。 注册地址:北京市海淀区知春路20号法定代表人:杨珊华 金融许可证机构编码:L0145H211000001 企 业 法 人 营 业 执 照 注 册 号 : 9111000071783212X7 税务登记证号码: 9111000071783212X7 内部控制制度体系具体内容如下: 1、公司治理 财务公司建立了完善的法人治理结构,设立了股东会、董事会、监事会和经理层,依 据公司章程和相关议事规则的规定行使相应职责。 2、财务公司的组织架构图如下 经营范围:1、对成员单位办理财务和融资顾问、信用鉴证及相关的咨询、代理业务; 2、 ...
天坛生物:天坛生物独立董事意见
2023-08-29 10:08
北京天坛生物制品股份有限公司 本次董事会审议了关联交易议案《关于对国药集团财务有限公司 的风险持续评估报告》,现就上述关联交易议案发表独立意见如下: (一)董事会在对上述关联交易事项进行表决时,关联董事采取 了回避表决。董事会的表决程序符合《公司法》、《股票上市规则》等 法律、法规和规范性文件及《公司章程》的有关规定; 1 (二)国药集团财务有限公司(以下简称"国药财务")具有合法 有效的《金融许可证》、《营业执照》,能够严格按照监管规定经营。公 司与国药财务之间的关联存贷款等交易是基于公司正常经营活动和发 展需要,遵循公平、自愿、诚信的原则开展,不存在影响公司资金独 立性、安全性的情形,不存在被关联方占用的情形,不存在损害公司 及股东利益的行为。 (三)同意公司《关于对国药集团财务有限公司的风险持续评估 报告》。 独立董事意见 北京天坛生物制品股份有限公司(以下简称"公司")第九届董事 会第三次会议于 2023 年 8 月 29 日在北京市朝阳区双桥路乙 2 号院办 公楼三层第一会议室召开,作为独立董事,我们参加了本次会议,根 据上海证券交易所《上海证券交易所股票上市规则》、《上市公司自 律监管指引第 1 ...
天坛生物:天坛生物第九届监事会第二次会议决议公告
2023-08-29 10:07
证券代码:600161 证券名称:天坛生物 编号:2023-033 二、 审议通过《2023 年半年度报告正本及其摘要》,并提出审核意见如下: 北京天坛生物制品股份有限公司 第九届监事会第二次会议决议公告 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈述或者重大 遗漏,并对其内容的真实性、准确性和完整性承担个别及连带责任。 北京天坛生物制品股份有限公司(以下简称"公司")第九届监事会第二次会议 于 2023 年 8 月 18 日以电子方式发出会议通知,于 2023 年 8 月 29 日在北京市朝阳区 双桥路乙 2 号院 1 号办公楼三层第一会议室召开。会议由监事会主席陈键先生主持, 会议应到监事三人,实到三人。按照《公司法》及本公司章程和《监事会议事规则》 规定,会议有效。与会监事共同审议了会议提出的议案,做出如下决议: 一、 审议通过《2023 年半年度募集资金存放与实际使用情况的专项报告》 表决结果:3 票同意,0 票反对,0 票弃权。 详见同日披露的《北京天坛生物制品股份有限公司 2023 年半年度募集资金存放 与实际使用情况的专项报告》(2023-034)。 (一)公司 2023 年 ...
天坛生物:天坛生物第九届董事会第三次会议决议公告
2023-08-29 10:07
证券代码:600161 证券简称:天坛生物 公告编号:2023-032 北京天坛生物制品股份有限公司 第九届董事会第三次会议决议公告 同意调整公司所属兰州血制静宁兰生单采血浆有限责任公司(以下简称"静 宁浆站")单采血浆业务用房建设用地购置费用,并相应调整项目总投资,调整 后项目总投资 3,332 万元(含土地购置费),项目资金由静宁浆站自筹。 表决结果:9 票同意,0 票反对,0 票弃权。 三、审议通过《关于武汉血制巴东武生生物制品有限公司购置土地及单采 血浆业务用房建设项目的议案》 同意公司所属国药集团武汉血液制品有限公司巴东武生生物制品有限公司 (以下简称"巴东浆站")购置单采血浆业务用房建设用地;同意巴东浆站完成 1 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者 重大遗漏,并对其内容的真实性、准确性和完整性承担个别及连带责任。 北京天坛生物制品股份有限公司(以下简称"公司") 第九届董事会第三次 会议于 2023 年 8 月 18 日以电子方式发出会议通知,于 2023 年 8 月 29 日以在北 京市朝阳区双桥路乙 2 号院办公楼三层第一会议室召开。会议由董事长杨汇川先 生 ...
天坛生物:天坛生物关于召开2022年度业绩暨现金分红说明会公告
2023-05-05 09:10
证券代码:600161 证券简称:天坛生物 公告编号:2023-021 北京天坛生物制品股份有限公司 关于召开 2022 年度业绩暨现金分红说明会公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重 大遗漏,并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示: 会议召开时间:2023 年 5 月 16 日(星期二)10:00-11:30 会 议 召 开 地 点 : 上 海 证 券 交 易 所 上 证 路 演 中 心 ( 网 址 : http://roadshow.sseinfo.com/) 会议召开方式:上证路演中心网络互动 投资者可于 2023 年 5 月 9 日(星期二)至 5 月 15 日(星期一)16:00 前登录 上证路演中心网站首页点击"提问预征集"栏目或通过公司投资者关系邮箱 ttswdb@sinopharm.com 进行提问。公司将在说明会上对投资者普遍关注的问题进 行回答。 一、 说明会类型 北京天坛生物制品股份有限公司(以下简称"公司")已于 2023 年 4 月 25 日 发布公司 2022 年年度报告和 2022 年年度利润分配预案公告,公司 ...
天坛生物(600161) - 2022 Q4 - 年度财报
2023-04-24 16:00
Financial Performance - The company's operating revenue for 2022 was CNY 4,261,304,622.88, representing a 3.63% increase compared to CNY 4,112,155,621.36 in 2021[22]. - The net profit attributable to shareholders for 2022 was CNY 881,029,002.17, a 15.92% increase from CNY 760,012,024.99 in 2021[22]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was CNY 853,863,946.15, up 12.93% from CNY 756,092,387.54 in 2021[22]. - The net cash flow from operating activities for 2022 was CNY 1,126,002,190.03, an increase of 14.86% compared to CNY 980,350,195.00 in 2021[22]. - The total assets at the end of 2022 were CNY 12,940,709,339.65, reflecting an 11.77% increase from CNY 11,577,632,332.02 at the end of 2021[22]. - The net assets attributable to shareholders at the end of 2022 were CNY 8,795,740,348.20, a 9.24% increase from CNY 8,052,028,807.53 at the end of 2021[22]. - The basic earnings per share for 2022 was 0.53 RMB, up 12.77% from 0.47 RMB in 2021[23]. - The company’s gross margin for biological products was 49.00%, an increase of 1.55 percentage points from the previous year[83]. Plasma Collection and Production - The company collected a total of 2,035 tons of plasma in 2022, marking an 11% increase year-on-year[31]. - The company expanded its plasma collection stations, establishing 22 new stations in regions such as Guizhou and Gansu, bringing the total to 70 operational stations[31]. - The company operates 102 plasma collection stations across 16 provinces/regions, with 70 currently active, expanding its reach[70]. - The company has increased its sales coverage to 33,703 terminals, a year-on-year growth of 5.72%, including 13,410 pharmacies and 3,100 secondary and above medical institutions[57]. - The production volume of blood products reached 1,273.05 million bottles, an increase of 6.50% compared to the previous year[84]. - The sales volume of blood products was 1,308.54 million bottles, up by 4.89% year-on-year[84]. - The company has established three new production bases, each with a designed capacity of 1,200 tons, to enhance production scale and operational efficiency[58]. Research and Development - The company has a comprehensive R&D pipeline focusing on rare diseases and has entered the registration phase for recombinant coagulation factor products, a first in the domestic industry[69]. - The company has invested in advanced R&D facilities and has over 100 researchers focused on blood product development, enhancing its innovation capabilities[56]. - The company has a comprehensive quality management system for new product development throughout its lifecycle, ensuring high standards in R&D[57]. - The company is in the clinical trial phase for a new COVID-19 immunoglobulin product, indicating ongoing innovation in response to the pandemic[109]. - The company has received approval for multiple new products, including human immunoglobulin and coagulation factor products, enhancing its product portfolio[111]. - The company is actively expanding its market presence through new product launches and regulatory approvals, which are expected to drive future growth[111]. - The company’s strategic focus on R&D and product innovation is aimed at maintaining competitive advantage in the biopharmaceutical market[112]. Market Expansion and Strategy - The company expanded its international market presence, achieving sales in Brazil and advancing overseas registration for key products like intravenous immunoglobulin and hepatitis B immunoglobulin[36]. - The company is committed to expanding its terminal hospital network, focusing on key hospitals to enhance market penetration[57]. - The company aims to enhance its market presence through these new establishments, focusing on increasing plasma supply capabilities[119]. - The company plans to strengthen its plasma resource layout through the expansion of existing plasma stations and the establishment of new ones, maintaining a leading position in the domestic industry[132]. - The company will implement a dual approach to R&D, focusing on both blood-derived and recombinant new products to enhance market competitiveness and meet clinical needs[132]. - The company is committed to international expansion and optimizing its marketing management system to increase domestic terminal coverage and deepen international cooperation[133]. Corporate Governance and Management - The company has a structured process for evaluating and appointing board members and supervisors, ensuring governance continuity[159]. - The company emphasizes a performance-based compensation structure for senior management, aligning incentives with company performance[157]. - The company has maintained a focus on effective governance and management oversight through regular board and supervisory meetings[163]. - The company held a total of 11 board meetings in the year, with all directors attending each meeting[164]. - The company’s supervisory board received a resignation from supervisor Liu Jinsui on April 22, 2022, due to work changes[158]. - The company reported a significant management change with the resignation of Chairman Yang Xiaoming due to work changes, effective December 5, 2022[160]. Environmental and Safety Compliance - Chengdu Rongsheng processed a total of 317,617 m³ of wastewater during the reporting period, with an average daily treatment of 870.18 m³/d, all meeting discharge standards[193]. - Shanghai Blood Products' wastewater treatment facility has a total processing capacity of 200 m³/d, upgraded to 450 tons/day in early 2023[197]. - The hazardous waste storage facilities at Chengdu Rongsheng comply with national standards for safety and environmental protection[196]. - All construction projects by Chengdu Rongsheng and Shanghai Blood Products have undergone environmental impact assessments and passed the completion acceptance of environmental protection facilities[199]. - The company has developed and filed an emergency response plan for sudden environmental incidents to effectively prevent and control pollution events[200]. Challenges and Risks - The company faces risks related to national policy changes and increased regulatory scrutiny in the blood products industry, which could impact production and profitability[137]. - There is a potential risk associated with the safety of blood products due to the biological nature of their raw materials, which may not fully eliminate unknown pathogens[138]. - The supply of raw materials, specifically human plasma, is currently tight due to low donor participation, directly impacting production capacity[140]. - Rising costs associated with plasma collection are putting pressure on profitability, influenced by increasing national income and inflation[141]. - Blood product prices are expected to fluctuate based on market supply and demand, with potential differentiation due to increased imports and domestic clinical applications[142].
天坛生物(600161) - 2023 Q1 - 季度财报
2023-04-24 16:00
Financial Performance - The company's operating revenue for Q1 2023 reached ¥1,291,975,871.24, representing an increase of 83.30% compared to the same period last year[4]. - Net profit attributable to shareholders was ¥261,909,016.67, marking a significant increase of 109.23% year-on-year[4]. - Basic earnings per share (EPS) stood at ¥0.16, which is an increase of 109.23% year-on-year[4]. - Operating profit for Q1 2023 was ¥427,356,672.03, up 106.7% from ¥206,670,065.85 in the same period last year[18]. - Net profit for Q1 2023 was ¥358,982,561.98, representing a 104.5% increase from ¥175,553,905.62 in Q1 2022[19]. - The net profit after deducting non-recurring gains and losses was ¥253,182,543.90, up 118.19% year-on-year[4]. - The company reported a significant increase in other receivables, which rose to RMB 31,983,884.62 from RMB 28,361,261.82, a growth of approximately 9.25%[13]. Cash Flow - The net cash flow from operating activities was ¥620,695,486.70, reflecting a substantial increase of 199.46% compared to the previous year[4]. - Cash flow from operating activities for Q1 2023 was ¥620,695,486.70, compared to ¥207,272,943.62 in Q1 2022, indicating a growth of 199.5%[21]. - The company reported a net cash inflow from operating activities of ¥1,446,562,862.88 for Q1 2023, compared to ¥883,891,324.30 in Q1 2022[21]. - The net cash flow from investing activities was -¥201,374,271.14 for the first quarter of 2023, compared to -¥266,163,915.06 in the same period last year[22]. - The company generated CNY 130,561,428.59 in net cash flow from investing activities in Q1 2023, a significant improvement from negative CNY 18,833,608.89 in Q1 2022[28]. Assets and Liabilities - Total assets at the end of Q1 2023 amounted to ¥13,512,920,082.80, a growth of 4.42% from the end of the previous year[5]. - The company's total liabilities increased to RMB 1,365,270,017.66, compared to RMB 1,157,348,349.10, indicating a rise of about 17.94%[14]. - Total liabilities as of Q1 2023 amounted to ¥1,797,598,125.04, an increase from ¥1,584,369,943.88 in the previous year[18]. - The company's total current assets increased to ¥2,366,625,651.49 as of March 31, 2023, from ¥2,172,791,737.09 a year earlier, reflecting a growth of approximately 8.9%[24]. - The company's cash and cash equivalents reached RMB 4,135,912,849.98, up from RMB 3,712,890,052.98, indicating an increase of about 11.39%[13]. Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 61,733[10]. - The largest shareholder, China Biotechnology Co., Ltd., holds 45.64% of the shares, totaling 752,083,740 shares[10]. Research and Development - Research and development expenses for Q1 2023 were ¥9,539,026.33, a decrease of 57.8% from ¥22,631,280.65 in Q1 2022[18]. - The company has not disclosed any new product developments or market expansion strategies in the current report[12]. Other Financial Metrics - The weighted average return on equity (ROE) was 2.93%, an increase of 1.39 percentage points compared to the previous year[4]. - The total cost of operations for Q1 2023 was ¥883,395,917.16, which is 70.7% higher than ¥517,977,148.28 in Q1 2022[18]. - The company's inventory decreased slightly to RMB 2,280,679,350.92 from RMB 2,332,002,006.69, a decline of about 2.21%[14]. - The company's long-term equity investments remained unchanged at RMB 173,924,750.15[14].
天坛生物(600161) - 2020 Q2 - 季度财报
2020-08-27 16:00
2020 年半年度报告 公司代码:600161 公司简称:天坛生物 北京天坛生物制品股份有限公司 2020 年半年度报告 1 / 166 2020 年半年度报告 重要提示 一、 本公司董事会、监事会及董事、监事、高级管理人员保证半年度报告内容的真实、准确、完 整,不存在虚假记载、误导性陈述或重大遗漏,并承担个别和连带的法律责任。 二、 未出席董事情况 | --- | --- | --- | --- | |----------|--------|--------|--------| | | | | | | 独立董事 | 王宏广 | 因公务 | 顾奋玲 | | 独立董事 | 方燕 | 因公务 | 顾奋玲 | 三、 本半年度报告未经审计。 四、 公司负责人付道兴、主管会计工作负责人张翼及会计机构负责人(会计主管人员)朱振海声 明:保证半年度报告中财务报告的真实、准确、完整。 五、 经董事会审议的报告期利润分配预案或公积金转增股本预案 无 六、 前瞻性陈述的风险声明 √适用 □不适用 本报告中所涉及的未来计划、发展战略等前瞻性描述不构成公司对投资者的实质承诺,敬请 投资者注意投资风险。 七、 是否存在被控股股东及其关 ...